Pharmacia Ab

Abbott Diabetes Care Inc.

Cambridge Enterprise Limited

David B Dunger

Gary Alan Hayter

Erwin Satrya Budiman

Marc Barry Taub

Roman Hovorka

Peter Henri Sonksen

Malgorzata E Wilinska

Martin O Savage

A system and method for reducing the number of hypoglycemic alarms presented to a user is presented. The system and methods include use of model based state estimation and variable-delayed threshold values to balance the risk of not presenting an alarm caused by an actual hypoglycemic state with the presentation of alarms caused by artifacts in the signals produced by a continuous glucose monitor.

Methods for reducing false hypoglycemia alarm occurrence

The invention relates to treatment of patients in need of increasing insulin sensitivity by administration of growth hormone or analogues thereof, preferably human growth hormone, in a low dose and the use of growth hormone or analogues thereof, preferably human growth hormone, for the manufacturing of a medicament useful for increasing insulin sensitivity in low dose therapy. The patient is preferably a normal subject, i.e. not growth hormone deficient patient and/or a non-obese patients. By low dose therapy is preferably meant less than 0.008 mg/kg/day, preferably 0.007 mg/kg/day or less, more preferably 0.005 mg/kg/day or less and most preferably 0.003 mg/kg/day or less. The therapy is preferably performed during short term treatment, preferably less than one month.

Use of growth hormone in low dose

Use of IGF-1

Growing community of inventors

Oxford, United Kingdom

David B Dunger